Euthymics Bioscience

company

About

Euthymics Bioscience, a neuroscience-focused biopharmaceutical company, develops medicines for central nervous system disorders.

  • 11 - 50

Details

Last Funding Type
Series A
Last Funding Money Raised
$4M
Industries
Biotechnology,Life Science,Pharmaceutical
Founded date
Jan 1, 2009
Number Of Employee
11 - 50
Operating Status
Active

Euthymics Bioscience, Inc. is a neuroscience-focused clinical-stage company developing next-generation treatments for depression. Euthymics’ initial focus is on patients who do not respond adequately to SSRIs.

EB-1010 for depression is expected to improve efficacy and reduce the leading side effects associated with poor adherence to standard antidepressants including weight gain, sexual dysfunction and cognitive impairment. Euthymics is a private Delaware corporation with headquarters in Cambridge, Massachusetts.

Euthymics is developing products for central nervous system disorders of significant unmet medical need, including major depressive disorder (MDD) and, under a collaboration with the government, alcohol use disorder (AUD).

According to the National Institutes of Health, MDD affects over 15 million American adults. According to the National Institute of Alcohol Abuse and Alcoholism (NIAAA), approximately 18 million Americans have alcohol use disorder (either alcohol dependence or alcohol abuse).

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$4M
Euthymics Bioscience has raised a total of $4M in funding over 2 rounds. Their latest funding was raised on Mar 9, 2011 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Mar 9, 2011 Series A $4M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Euthymics Bioscience is funded by 1 investors. H&Q Venture Capital are the most recent investors.
Investor Name Lead Investor Funding Round
H&Q Venture Capital Series A